Contact this trialFirst, we need to learn more about you.
GLP-1 Receptor Agonist
Orforglipron vs Semaglutide for Type 2 Diabetes
Recruiting2 awardsPhase 3
Tampa, Florida
This trial will compare a new diabetes drug with semaglutide to see if it's safe and effective for people with Type 2 diabetes who take metformin. The trial will last 61 weeks.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.